RetinalaminРетиналамин
What is it?
A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.
Research context
A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.
- Working classification
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Clinical reports linked; see study-specific limitations
- Study methods
- —Original reports separated from narrative reviews and patents
- Independent replication
- —Independent replication not established by this collection
- Source access
- —Linked abstracts, analytical papers, reviews and patents; individual scope shown below
- Safety evidence
- —Incomplete assessment; findings do not establish safety for personal use
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Where this preparation fits.
Retina: the molecular link
Retinalamin → Normophthal (adjacent short-peptide program)
Shared tissue theme, not a verified product-to-sequence derivation in this collection.
Clinical boundary
The glaucoma report compares active Retinalamin administration routes; its abstract uses the unit “498 patients (eyes)”.
An active-route comparison cannot establish benefit versus no treatment. Retinalamin findings cannot be transferred to Normophthal.
Related preparations
The contextual sources below can concern a related extract, review or molecular link. They are not all direct studies of this profile’s compound.
Linked sources
Explore the research map and unresolved leads ↗
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
- Population / setting
- Originating group’s clinical and gerontology literature
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- Review by investigators in the originating program; not independent replication.
- Clinical findings must be traced to the exact preparation and original study.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.
Peptide bioregulators: delivery and efficacy
Erichev VP, Lovpache DN, Yaremenko TV · Vestn Oftalmol 136(2):56-62. PMID 32366071
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
- Population / setting
- Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- All compared groups received active preparation; this does not isolate benefit versus no Retinalamin.
- Patient/eye unit wording should be checked in full text. Findings do not establish benefit for Normophthal.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.